Mitchell Carroll
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mitchell Carroll has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
G Ibbott
Department of Radiation Physics, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030 USA
6 shared publications- John Adamovics
Department of Chemistry and Biology, Rider University, Skillman, NJ
4 shared publications M Gillin
University of Texas MD Anderson Cancer Center
3 shared publicationsR Grant
University of Texas MD Anderson Cancer Center
3 shared publicationsD Followill
1 shared publication- Geoffrey S. Ibbott
Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
1 shared publication
Latest Publications
- 1 December 2017
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 125 (3) , 426-432
Investigation of magnetic field effects on the dose–response of 3D dosimeters for magnetic resonance – image guided radiation therapy applications
- 1 December 2017
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 125 (3) , 426-432
Investigation of magnetic field effects on the dose–response of 3D dosimeters for magnetic resonance – image guided radiation therapy applications
- Open Access
- 1 May 2017
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 847 (1) , 012027
The quenching effect in PRESAGE®by a proton beam: Investigation of formulation dependence
The radiochromic dosimeter PRESAGE® has shown potential in conventional radiotherapies, but it suffers from dose under-responding, or signal quenching, in proton therapy as a result of dependence on variations in the linear energy transfer (LET). Early investigations have shown the under-response is affected by the chemical concentration of the active components, but as yet this relationship has not been comprehensively measured. This study investigated the impact of PRESAGE® formulation changes on signal quenching to determine the magnitude by which the quenching can be minimized.
- 1 May 2017
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 847 (1) , 012027
Open AccessThe quenching effect in PRESAGE®by a proton beam: Investigation of formulation dependence
The radiochromic dosimeter PRESAGE® has shown potential in conventional radiotherapies, but it suffers from dose under-responding, or signal quenching, in proton therapy as a result of dependence on variations in the linear energy transfer (LET). Early investigations have shown the under-response is affected by the chemical concentration of the active components, but as yet this relationship has not been comprehensively measured. This study investigated the impact of PRESAGE® formulation changes on signal quenching to determine the magnitude by which the quenching can be minimized.
- Open Access
- 12 January 2015
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 573
Feasibility of PET/CT 3-D dosimetry for proton-activated PRESAGE®dosimeters
- 12 January 2015
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 573
Open AccessFeasibility of PET/CT 3-D dosimetry for proton-activated PRESAGE®dosimeters
- Open Access
- 26 June 2013
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 444
Investigation of photon and proton overlapping fields in PRESAGE® dosimeters
- 26 June 2013
- Published by IOP Publishing in Journal of Physics: Conference Series
- Vol. 444
Open AccessInvestigation of photon and proton overlapping fields in PRESAGE® dosimeters
- 6 June 2013
- Published by Wiley in Medical Physics
- Vol. 40 (6Part11) , 220
SU-E-T-73: Investigation of 3D Dosimetry for Proton Therapy Using PRESAGE
- 6 June 2013
- Published by Wiley in Medical Physics
- Vol. 40 (6Part11) , 220
SU-E-T-73: Investigation of 3D Dosimetry for Proton Therapy Using PRESAGE
- 28 June 2012
- Published by Wiley in Medical Physics
- Vol. 39 (6Part11) , 3733
SU‐E‐T‐132: Investigation of Photon and Proton Overlapping Fields in PRESAGE‐ Dosimeters
The proton formulation of PRESAGE® showed good dose agreement between single and multiple field irradiations. While the photon formulation had slightly less agreement, additional field setup comparisons may show improved results. These results will aid future measurements of overlapping field treatment plans delivered to PRESAGE® for treatment verification for proton and photon 3D dosimetry.
- 28 June 2012
- Published by Wiley in Medical Physics
- Vol. 39 (6Part11) , 3733
SU‐E‐T‐132: Investigation of Photon and Proton Overlapping Fields in PRESAGE‐ Dosimeters
The proton formulation of PRESAGE® showed good dose agreement between single and multiple field irradiations. While the photon formulation had slightly less agreement, additional field setup comparisons may show improved results. These results will aid future measurements of overlapping field treatment plans delivered to PRESAGE® for treatment verification for proton and photon 3D dosimetry.
- 28 June 2012
- Published by Wiley in Medical Physics
- Vol. 39 (6Part19) , 3834
SU-E-T-560: Inter- and Intra-Fraction Variations in Esophageal Dose for Lung Cancer Patients, and the Impact of Setup Technique and Treatment Modality
Purpose: To understand the dose‐response of the esophagus in photon and proton therapy, it is important to appreciate the variations in delivered dose caused by inter‐ and intra‐fraction motion. Methods: Four lung cancer patients were identified who had experienced grade 3 esophagitis during their treatment, and for whom their esophagus was close, but not encompassed by, the treatment volume. Each patient had been treated with proton therapy using 35–37 2Gy fractions, and had received weekly 4DCT imaging. IMRT plans were also created using the same treatment planning constraints. In‐house image registration software was used to deform the esophagus contour from the treatment plan to each phase of the 4DCT for each weekly image set. Daily setup using both bony and soft tissue (GTV) registration was simulated, and the treatment dose calculated for each CT image. Changes to the esophagus DVH relative to the treatment plan were quantified in terms of the relative volume of the esophagus receiving 45, 55, and 65Gy (V45, V55 and V65). Results: For all combinations of treatment modality (photon, proton) and setup method (bony, GTV), intra‐fraction motion resulted in a range of V45, V55 and V65 from 3.6 to 5.5%. Inter‐fraction motion comparing daily exhale or inhale phases showed the range of V45, V55 and V65 from 8.5 to 18.6% (exhale) and 9.8 to 16.3% (inhale). Conclusions: Inter‐fractional motion resulted in larger variations in dose delivered to the esophagus than intra‐fractional motion. The inter‐fraction range for V45, V55 and V65 varied by around 10% between patients. The treatment modality (photon, proton) and setup technique (bony, GTV) had minimal impact on the results.
- 28 June 2012
- Published by Wiley in Medical Physics
- Vol. 39 (6Part19) , 3834
SU-E-T-560: Inter- and Intra-Fraction Variations in Esophageal Dose for Lung Cancer Patients, and the Impact of Setup Technique and Treatment Modality
Purpose: To understand the dose‐response of the esophagus in photon and proton therapy, it is important to appreciate the variations in delivered dose caused by inter‐ and intra‐fraction motion. Methods: Four lung cancer patients were identified who had experienced grade 3 esophagitis during their treatment, and for whom their esophagus was close, but not encompassed by, the treatment volume. Each patient had been treated with proton therapy using 35–37 2Gy fractions, and had received weekly 4DCT imaging. IMRT plans were also created using the same treatment planning constraints. In‐house image registration software was used to deform the esophagus contour from the treatment plan to each phase of the 4DCT for each weekly image set. Daily setup using both bony and soft tissue (GTV) registration was simulated, and the treatment dose calculated for each CT image. Changes to the esophagus DVH relative to the treatment plan were quantified in terms of the relative volume of the esophagus receiving 45, 55, and 65Gy (V45, V55 and V65). Results: For all combinations of treatment modality (photon, proton) and setup method (bony, GTV), intra‐fraction motion resulted in a range of V45, V55 and V65 from 3.6 to 5.5%. Inter‐fraction motion comparing daily exhale or inhale phases showed the range of V45, V55 and V65 from 8.5 to 18.6% (exhale) and 9.8 to 16.3% (inhale). Conclusions: Inter‐fractional motion resulted in larger variations in dose delivered to the esophagus than intra‐fractional motion. The inter‐fraction range for V45, V55 and V65 varied by around 10% between patients. The treatment modality (photon, proton) and setup technique (bony, GTV) had minimal impact on the results.
- 1 June 2011
- Published by Wiley in Medical Physics
- Vol. 38 (6Part16) , 3571
SU-E-T-363: Investigation of PRESAGE® Dosimeters for Proton Therapy
- 1 June 2011
- Published by Wiley in Medical Physics
- Vol. 38 (6Part16) , 3571
SU-E-T-363: Investigation of PRESAGE® Dosimeters for Proton Therapy